The impact of EGFR-mutant NSCLC precision therapy with EGFR tyrosine kinase inhibitors, such as erlotinib and gefitinib is limited by acquired resistance despite good initial responses but the underlying mechanisms remain elusive. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.